Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. HIV infection is independently associated with a higher concentration of alpha-1 antitrypsin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Primary resistance to integrase strand-transfer inhibitors in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of HIV or second syphilis infection in Danish men with newly acquired syphilis in the period 2000-2010

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVES: To evaluate the long-term pharmacokinetics and safety of adding ritonavir 100 mg twice-daily to a nelfinavir 1250 mg twice-daily regimen in HIV-infected patients. METHODS: This was a prospective, randomized, open-label, controlled 24-week study. Sixteen patients receiving a nelfinavir 1250 mg twice-daily regimen with plasma viral load <1000 HIV-1 RNA copies/mL were randomized to continue treatment or to have ritonavir 100 mg twice-daily added. Safety, including fasting lipid levels, was evaluated at weeks 4, 12 and 24. Patients who were randomized to have ritonavir added (n=9) participated in three 12-h pharmacokinetic evaluations at baseline, week 4 and week 24. RESULTS: Increases in median nelfinavir steady-state plasma concentrations at 12 h (C(12)) from 512 to 773 ng/mL [median difference 450 ng/mL; 95% confidence interval (CI) 116--1510 ng/mL] and in median active nelfinavir metabolite M 8 C(12) from 107 to 603 ng/mL (median difference 545 ng/mL; 95% CI 370--891) were seen after the addition of low-dose ritonavir (baseline to week 24). There were no differences between the nelfinavir or M 8 pharmacokinetic parameters at weeks 4 and 24. No significant changes or differences in the concentration of fasting total cholesterol, low-density lipoprotein (LDL) cholesterol or total triglycerides or in the occurrence of adverse events were observed within or between the two groups. CONCLUSIONS: Nelfinavir and especially M 8 concentrations are increased when low-dose ritonavir is added to a nelfinavir-containing regimen. The combination seems to be safe and the nelfinavir/ritonavir regimen could be an option in patients with low nelfinavir+M 8 concentrations.
Original languageEnglish
JournalHIV Medicine
Volume6
Issue number5
Pages (from-to)334-40
Number of pages6
ISSN1464-2662
DOIs
Publication statusPublished - 2005

    Research areas

  • Adult, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Lipids, Male, Middle Aged, Nelfinavir, Prospective Studies, Ritonavir, Viral Load

ID: 32505803